Mind Medicine (MindMed) Inc. — Q2 2022 Form 10-Q
Issuer note: The request metadata names Definium Therapeutics, Inc., but the supplied filing is for Mind Medicine (MindMed) Inc. This summary reflects the filing provided. Reporting period ended June 30, 2022; filed August 11, 2022. Amounts are U.S. dollars unless stated otherwise; financial statement amounts are in millions unless noted.
Business context and reporting period
MindMed is a clinical-stage biopharmaceutical company developing treatments for brain health disorders. Its programs include MM-120 (LSD), MM-110 (zolunicant) and MM-402 (R(-)-MDMA). The company had no revenue and is funding operations primarily through equity financing.
Financial performance and liquidity
| Metric | Q2 2022 / June 30, 2022 | Comparable period / prior year-end |
|---|---|---|
| Revenue | None | None reported |
| Research and development expense | $9.3 million for quarter; $19.6 million for six months | $8.1 million and $14.9 million, respectively, in 2021 |
| General and administrative expense | $7.6 million for quarter; $15.9 million for six months | $37.1 million and $44.2 million, respectively, in 2021 |
| Net loss | $17.0 million for quarter; $35.4 million for six months | $45.3 million and $59.0 million, respectively, in 2021 |
| Operating cash used | $28.0 million for six months | $21.2 million in 2021 |
| Cash and cash equivalents | $105.7 million | $133.5 million at December 31, 2021 |
| Working capital | $101.2 million | Not stated for the comparable date |
| Total liabilities | $9.8 million; no material debt balance reported | $12.3 million at December 31, 2021 |
| Accumulated deficit | $173.1 million | $137.7 million at December 31, 2021 |
Margins are not meaningful because the company reported no revenue. Total assets were $134.3 million and shareholders’ equity was $124.5 million at June 30, 2022. Cash declined $27.8 million in the first half of 2022. Financing cash inflow was $0.4 million, mainly from warrant and option exercises, compared with $97.9 million in the first half of 2021, which included equity offering proceeds.
Material changes versus the prior comparable period
- Six-month R&D expense rose 31% to $19.6 million, principally reflecting increased personnel and compensation costs and higher MM-120 activity; Q2 R&D also included higher LSD-program costs and commencement of an R(-)-MDMA study.
- Six-month G&A expense fell 64% to $15.9 million. The comparison was substantially affected by $24.4 million of additional non-cash stock-based compensation tied to award modifications in 2021.
- Six-month net loss narrowed to $35.4 million from $59.0 million, largely due to the lower 2021-comparison G&A charge. Operating cash use nevertheless increased to $28.0 million from $21.2 million.
- Cash fell from $133.5 million at year-end 2021. The company had not used its new at-the-market (ATM) facility by June 30.
Outlook, risks, contingencies and unusual items
- Management expected existing cash to fund its current 2022–2023 operating plan and extend the cash runway into 2024; it also stated working capital was sufficient for at least 12 months from issuance of the financial statements. These are forward-looking estimates and may change.
- MM-120 Phase 2 studies in generalized anxiety disorder and ADHD were ongoing, with topline results expected in late 2023. The company planned an MM-402 Phase 1 trial in 2023 and anticipated an investigator-initiated R(-)-MDMA trial in Q3 2022. Further MM-110 development was contingent on non-dilutive funding or third-party collaboration.
- The company filed a shelf registration allowing up to $200 million of securities and established an ATM program of up to $100 million, subject to a 3% sales commission. No ATM shares had been sold as of June 30, 2022; future equity financing could dilute shareholders.
- Approximately $33.7 million of research, development and other commitments were disclosed, most cancelable with notice. Potential milestone, royalty and indemnification obligations may arise, but amounts and timing are uncertain.
- Nasdaq notified the company on May 27, 2022 that its share price did not meet the $1 minimum bid requirement; the stated compliance deadline was November 23, 2022. After quarter-end, the board approved a proposed 1-for-15 reverse share split, expected to take effect after August 26, subject to required approvals. The company had not regained compliance as of the filing date.
- Management reported no significant COVID-19 disruption to date but acknowledged potential effects on clinical timelines. No material litigation was reported. Disclosure controls were assessed as effective at a reasonable-assurance level.
Important facts for investors to verify
- Confirm the intended issuer: the supplied 10-Q is Mind Medicine (MindMed) Inc., not Definium Therapeutics, Inc.
- Track actual cash burn and whether management’s runway estimate into 2024 remains achievable as trial spending grows.
- Verify clinical trial initiation, progress and results against the stated MM-120 and MM-402 timelines, and funding conditions for MM-110.
- Monitor Nasdaq bid-price compliance and the completion, timing and market effects of the proposed reverse split.
- Review subsequent use of the shelf registration or ATM, potential shareholder dilution, and the scope and cancellation terms of the $33.7 million commitments.